Q8IXJ6 (SIR2_HUMAN) Homo sapiens (Human)
NAD-dependent protein deacetylase sirtuin-2 UniProtKBInterProSTRINGInteractive Modelling
389 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3; Isoform 4; Isoform 5);
3 identical sequences: Pan troglodytes: K7BWL3, A0A6D2Y4Q4; Gorilla gorilla gorilla: G3QJ69
Available Structures
50 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Sirt2 in complex with a 13-mer trifluoroacetylated Ran peptide |
Heteromer P62826; | 100.0 | 1×SO4; 1×ZN; | |||
| Human SIRT2 in complex with myristoylated peptide (H3K9myr) |
Heteromer P68431; | 100.0 | 1×ZN; | |||
| Human SIRT2 in complex with 2-O-myristoyl-ADP-ribose |
Heteromer | 100 | 4×ZN; 4×OMR; | |||
| Human SIRT2 in complex with myristoylated peptide (TNF-alphaK20myr) |
Heteromer P01375; | 100.0 | 1×ZN; | |||
| Crystal structure of SIRT2 with FAM-PEG4-H4K16(myristoyl) peptide |
Heteromer P62805; | 100.0 | 1×ZN; 1×MYR; | |||
| Crystal structure of Sirt2-ADPR at an improved resolution | homo-2-mer | 100 | 2×ZN; 2×AR6; 1×PGE; | |||
| Human SIRT2 in complex with small molecule 359 | homo-2-mer | 100.0 | 2×ZN; 4×SO4; 7×EDO; 2×DMS; 2×E7K; | |||
| Crystal structure of human Sirt2 in complex with a brominated 2nd generation SirReal inhibitor and … | homo-2-mer | 100.0 | 2×ZN; 2×5GN; 2×NAD; | |||
| Crystal structure of human Sirt2 in complex with a SirReal probe fragment | homo-2-mer | 100.0 | 2×ZN; 2×5GR; 2×EDO; 2×EPE; 2×BU3; | |||
| Structure of human Sirtuin 2 in complex with a selective thienopyrimidinone based inhibitor | homo-2-mer | 100.0 | 2×ZN; 1×7KJ; 14×SO4; 1×PG4; 1×P6G; | |||
| Structure of human SIRT2 in complex with ADP-ribose | homo-2-mer | 100.0 | 2×ZN; 6×ACT; 2×AR6; 1×GOL; 1×PGE; | |||
| Crystal structure of human Sirt2 in complex with ADPR and EX-243 | homo-2-mer | 100 | 2×ZN; 2×AR6; 4×OCZ; 1×PEG; | |||
| Human Sirt2 in complex with ADP ribose and nicotinamide | homo-2-mer | 100 | 2×AR6; 1×NCA; 1×PEG; 3×EDO; 1×NA; 2×ZN; 1×PGE; | |||
| Crystal structure of human Sirt2 in complex with ADPR and CHIC35 | homo-2-mer | 100 | 2×ZN; 2×AR6; 4×4I5; | |||
| SIRT2(56-356) with covalent intermediate between mechanism-based inhibitor Glucose-TM-1beta and 1'-… | homo-2-mer | 100.0 | 2×ZN; 2×KXJ; 2×KXG; 4×NA; 2×SO4; 4×GOL; | |||
| Re-refined structure of the human Sirt2 apoform | monomer | 99.68 | 1×ZN; 1×P6G; 1×PGE; 1×EDO; | |||
| HUMAN SIRT2 HISTONE DEACETYLASE | monomer | 100.0 | 1×ZN; | |||
| Crystal structure of human Sirtuin 2 in complex with a selective inhibitor | monomer | 100.0 | 1×ZN; 1×8NO; | |||
| Sirt2 in complex with a myristoyl peptide | monomer | 100.0 | 1×ZN; 2×EDO; 1×3Y0; | |||
| Sirt2 in complex with a myristoyl peptide | monomer | 100.0 | 1×ZN; 1×EDO; 1×CNA; 1×3LX; | |||
| Sirtuin 2 protein with H3K18 myristoylated peptide and intact NAD molecule | monomer | 99.66 | 1×ZN; 1×NAD; 1×3LX; | |||
| Sirtuin 2 demyristoylation native intermediate I & II mixture | monomer | 100.0 | 1×NCA; 1×YOY; 1×YDD; | |||
| Human SIRT2 catalyse short chain fatty acyl lysine | monomer | 100.0 | 1×ZN; 1×CNA; | |||
| Crystal Structure of SIRT2 in complex with the macrocyclic peptide S2iL5 | monomer | 100.0 | 1×ZN; 1×MES; | |||
| Human Sirt2 in complex with SirReal2 and Ac-Lys-H3 peptide | monomer | 100.0 | 1×ZN; 1×3TE; | |||
| Crystal structure of Sirt2 in complex with selective inhibitor L5C | monomer | 100.0 | 1×ZN; 1×L5C; | |||
| Crystal structure of human Sirt2 in complex with the super-slow substrate TNFn-5 and NAD+ | monomer | 100.0 | 1×ZN; 3×EDO; 1×NAD; 1×WU3; | |||
| Crystal structure of Sirt2 in complex with selective inhibitor L55 | monomer | 100.0 | 1×ZN; 1×L55; 1×PEG; | |||
| Crystal structure of Sirt2 in complex with selective inhibitor A2I | monomer | 100.0 | 1×A2I; 1×ZN; 2×BME; | |||
| Crystal structure of human Sirt2 in complex with a triazole-based SirReal | monomer | 100.0 | 1×KZU; 4×EDO; 1×BTB; 2×BU3; 1×ZN; 1×CL; | |||
| Crystal structure of Sirt2 in complex with selective inhibitor A29 | monomer | 100.0 | 1×ZN; 1×A2X; 4×BME; | |||
| Crystal structure of human Sirt2 in complex with the super-slow substrate TNFn-3 | monomer | 100.0 | 1×ZN; 1×PEG; 3×EDO; 1×WWE; | |||
| Human Sirt2 in complex with SirReal2 and NAD+ | monomer | 100.0 | 1×ZN; 1×3TE; 1×NAD; | |||
| Human SIRT2 in complex with a specific inhibitor, NPD11033 | monomer | 100.0 | 1×ZN; 1×8K9; | |||
| Human SIRT2 crystal structure in complex with BHJH-TM1 | monomer | 100.0 | 1×ZN; 1×3LX; | |||
| Human Sirt2 in complex with SirReal1 and Ac-Lys-OTC peptide | monomer | 100.0 | 1×ZN; 1×3TK; | |||
| Crystal structure of human Sirt2 in complex with the peptide-based pseudo-inhibitor TNFn-4.1 | monomer | 100.0 | 1×ZN; 1×BU3; 1×EDO; 1×WH8; 1×WGN; | |||
| Crystal structure of human Sirt2 in complex with the super-slow substrate TNFn-6 and NAD+ | monomer | 100.0 | 1×ZN; 4×EDO; 1×BTB; 1×DMS; 1×BU3; 1×PGE; 1×NAD; 1×WU8; | |||
| Crystal structure of human Sirt2 in complex with the super-slow substrate TNFn-5 | monomer | 100.0 | 1×ZN; 2×EDO; 1×WU3; | |||
| Crystal structure of human Sirt2 in complex with a 1,2,4-oxadiazole based inhibitor | monomer | 100.0 | 1×ZN; 1×I1R; 1×BTB; 5×EDO; | |||
| Crystal structure of human Sirt2 in complex with a TNFa-Myr analogue TNFn-34 | monomer | 100.0 | 1×ZN; 1×WWK; | |||
| Human SIRT2 in complex with myristoyl thiourea inhibitor, No.13 | monomer | 100.0 | 1×ZN; 1×F4R; | |||
| Human SIRT2 in complex with myristoyl thiourea inhibitor, No.23 | monomer | 100.0 | 1×ZN; 1×F4R; | |||
| Sirtuin 2 protein with H3K18 myristoylated peptide | monomer | 99.65 | 1×ZN; 1×MYR; | |||
| Structure of human SIRT2 in complex with 1,2,4-Oxadiazole inhibitor and ADP ribose. | monomer | 100 | 1×ZN; 1×AR6; 1×7KE; 2×EDO; 5×DMS; 2×GOL; | |||
| Crystal structure of human Sirt2 without Sirt2-specific insertion | monomer | 100.0 | 1×ZN; | |||
| Sirtuin 2 demyristoylation native final product | monomer | 100.0 | 1×OMR; 1×ZN; | |||
| Crystal structure of human Sirt2 in complex with the super-slow substrate TNFn-6 | monomer | 100.0 | 1×ZN; 1×EDO; 1×BTB; 1×BU3; 1×WU8; | |||
| Crystal structure of human Sirt2 in complex with the super-slow substrate TNFn-3 and NAD+ | monomer | 100.0 | 1×ZN; 1×NAD; 1×EDO; 1×WWE; | |||
| Human Sirt2 in complex with ADP-ribose and the inhibitor quercetin | monomer | 100 | 1×ZN; 1×AR6; 1×QUE; | |||
2 SWISS-MODEL models
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 3zgo.1.A | monomer | 0.81 | 1×ZN; | 99.69 | ||
| 5y5n.1.A | monomer | 0.78 | 1×ZN; 1×8NO; | 99.07 | ||
6 SWISS-MODEL models built on isoform sequence
| Isoform | Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|---|
| Isoform 2 | 3zgv.1.A | monomer | 0.87 | 1×ZN; | 100.00 | ||
| Isoform 3 | 3zgo.1.A | monomer | 0.82 | 1×ZN; | 98.14 | ||
| Isoform 3 | 5y5n.1.A | monomer | 0.79 | 1×ZN; 1×8NO; | 97.83 | ||
| Isoform 4 | 3zgo.1.A | monomer | 0.79 | 1×ZN; | 97.89 | ||
| Isoform 4 | 5y5n.1.A | monomer | 0.78 | 1×ZN; 1×8NO; | 97.90 | ||
| Isoform 5 | 5mar.1.A | monomer | 0.85 | 1×ZN; 1×AR6; 1×7KE; | 98.94 | ||